다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea, v.38 no.2, 2015년, pp.290 - 298
Kim, Hyeon Jin , Kim, Jin-Kyung
AI-Helper
Cucurbitacin-I is a naturally occurring tetracyclic triterpenoid compound with diverse physiological actions that include inducing apoptosis and blocking cell cycle progression of various cancer cells. However, its antiangiogenic activity has not yet been examined. Accordingly, we investigated the a...
Journal of Pharmacological Sciences N Ali 98 130 2005 10.1254/jphs.FP0040850 Ali, N., M. Yoshizumi, Y. Fujita, Y. Izawa, Y. Kanematsu, K. Ishizawa, K. Tsuchiya, S. Yano, S. Sone, and T. Tamaki. 2005. A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. Journal of Pharmacological Sciences 98: 130-141.
10.1007/s10456-009-9146-4 Arnaoutova, I., J. George, H.K. Kleinman, and G. Benton. 2009. The endothelial cell tube formation assay on basement membrane turns 20: State of the science and the art. Angiogenesis 12: 267-274.
Cancer Research MA Blaskovich 63 1270 2003 Blaskovich, M.A., J. Sun, A. Cantor, J. Turkson, R. Jove, and S.M. Sebti. 2003. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Research 63: 1270-1279.
10.1038/35025220 Carmeliet, P., and R.K. Jain. 2000. Angiogenesis in cancer and other diseases. Nature 407: 249-257.
Natural Product Reports JC Chen 22 386 2005 10.1039/b418841c Chen, J.C., M.H. Chiu, R.L. Nie, G.A. Cordell, and S.X. Qiu. 2005. Cucurbitacins and cucurbitane glycosides: Structures and biological activities. Natural Product Reports 22: 386-399.
Chimia (Aarau) P Christen 66 320 2012 10.2533/chimia.2012.320 Christen, P., and M. Cuendet. 2012. Plants as a source of therapeutic and health products. Chimia (Aarau) 66: 320-323.
Cancer Research PC Colorado 60 2520 2000 Colorado, P.C., A. Torre, G. Kamphaus, Y. Maeshima, H. Hopfer, K. Takahashi, R. Volk, E.D. Zamborsky, S. Herman, P.K. Sarkar, M.B. Ericksen, M. Dhanabal, M. Simons, M. Post, D.W. Kufe, R.R. Weichselbaum, V.P. Sukhatme, and R. Kalluri. 2000. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Research 60: 2520-2526.
Current Oncology Reports G Daniele 14 111 2012 10.1007/s11912-012-0225-0 Daniele, G., J. Corral, L.R. Molife, and J.S. de Bono. 2012. FGF receptor inhibitors: Role in cancer therapy. Current Oncology Reports 14: 111-119.
Cancer Discovery MV Dieci 3 264 2013 10.1158/2159-8290.CD-12-0362 Dieci, M.V., M. Arnedos, F. Andre, and J.C. Soria. 2013. Fibroblast growth factor receptor inhibitors as a cancer treatment: From a biologic rationale to medical perspectives. Cancer Discovery 3: 264-279.
Molecular Cell BP Eliceiri 4 915 1999 10.1016/S1097-2765(00)80221-X Eliceiri, B.P., R. Paul, P.L. Schwartzberg, J.D. Hood, J. Leng, and D.A. Cheresh. 1999. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Molecular Cell 4: 915-924.
Nature Reviews Cancer LM Ellis 8 579 2008 10.1038/nrc2403 Ellis, L.M., and D.J. Hicklin. 2008. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nature Reviews Cancer 8: 579-591.
Phytochemistry JC Espín 68 2986 2007 10.1016/j.phytochem.2007.09.014 Espín, J.C., M.T. García-Conesa, and F.A. Tomás-Barberán. 2007. Nutraceuticals: Facts and fiction. Phytochemistry 68: 2986-3008.
Trends in Pharmacological Sciences TP Fan 27 297 2006 10.1016/j.tips.2006.04.006 Fan, T.P., J.C. Yeh, K.W. Leung, P.Y. Yue, and R.N. Wong. 2006. Angiogenesis: From plants to blood vessels. Trends in Pharmacological Sciences 27: 297-309.
Critical Reviews in Oncology/Hematology FS Farhat 84 149 2012 10.1016/j.critrevonc.2012.02.012 Farhat, F.S., A. Tfayli, N. Fakhruddin, R. Mahfouz, Z.K. Otrock, R.S. Alameddine, A.H. Awada, and A. Shamseddine. 2012. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Critical Reviews in Oncology/Hematology 84: 149-160.
European Journal of Cancer J Fayette 41 1109 2005 10.1016/j.ejca.2005.02.017 Fayette, J., J.C. Soria, and J.P. Armand. 2005. Use of angiogenesis inhibitors in tumour treatment. European Journal of Cancer 41: 1109-1116.
Nature Medicine N Ferrara 9 669 2003 10.1038/nm0603-669 Ferrara, N., H.P. Gerber, and J. LeCouter. 2003. The biology of VEGF and its receptors. Nature Medicine 9: 669-676.
Journal of Biological Chemistry J Folkman 267 10931 1992 10.1016/S0021-9258(19)49853-0 Folkman, J., and Y. Shing. 1992. Angiogenesis. Journal of Biological Chemistry 267: 10931-10934.
Cardiovascular Research SW Han 98 73 2013 10.1093/cvr/cvt019 Han, S.W., Y.K. Jung, E.J. Lee, H.R. Park, G.W. Kim, J.H. Jeong, M.S. Han, and J.Y. Choi. 2013. DICAM inhibits angiogenesis via suppression of AKT and p38 MAP kinase signalling. Cardiovascular Research 98: 73-82.
Carcinogenesis SW Huang 33 1022 2012 10.1093/carcin/bgs127 Huang, S.W., J.C. Lien, S.C. Kuo, and T.F. Huang. 2012. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling. Carcinogenesis 33: 1022-1030.
Cancer Treatment Reviews R Iacovelli 40 271 2014 10.1016/j.ctrv.2013.09.003 Iacovelli, R., D. Alesini, A. Palazzo, P. Trenta, M. Santoni, L. De Marchis, S. Cascinu, G. Naso, and E. Cortesi. 2014. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treatment Reviews 40: 271-275.
BMC Cancer G Ishdorj 11 268 2011 10.1186/1471-2407-11-268 Ishdorj, G., J.B. Johnston, and S.B. Gibson. 2011. Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B leukemic cells. BMC Cancer 11: 268.
Oncogene MJ Karkkainen 19 5598 2000 10.1038/sj.onc.1203855 Karkkainen, M.J., and T.V. Petrova. 2000. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19: 5598-5605.
Journal of Biological Chemistry L Lamalice 281 34009 2006 10.1074/jbc.M603928200 Lamalice, L., F. Houle, and J. Huot. 2006. Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. Journal of Biological Chemistry 281: 34009-34020.
Molecular Cancer Therapeutics JH Lee 9 389 2010 10.1158/1535-7163.MCT-09-0775 Lee, J.H., S. Choi, Y. Lee, H.J. Lee, K.H. Kim, K.S. Ahn, H. Bae, H.J. Lee, E.O. Lee, K.S. Ahn, S.Y. Ryu, J. Lü, and S.H. Kim. 2010. Herbal compound farnesiferol C exerts antiangiogenic and antitumor activity and targets multiple aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) signaling cascades. Molecular Cancer Therapeutics 9: 389-399.
Biochemistry (Moscow) SV Lutsenko 68 286 2003 10.1023/A:1023002216413 Lutsenko, S.V., S.M. Kiselev, and S.E. Severin. 2003. Molecular mechanisms of tumor angiogenesis. Biochemistry (Moscow) 68: 286-300.
British Journal of Pharmacology A Pyriochou 152 1207 2007 10.1038/sj.bjp.0707534 Pyriochou, A., S. Tsigkos, T. Vassilakopoulos, T. Cottin, Z. Zhou, E. Gourzoulidou, C. Roussos, H. Waldmann, A. Giannis, and A. Papapetropoulos. 2007. Anti-angiogenic properties of a sulindac analogue. British Journal of Pharmacology 152: 1207-1214.
Current Pharmaceutical Design JL Ríos 18 1663 2012 10.2174/138161212799958549 Ríos, J.L., I. Andújar, J.M. Escandell, R.M. Giner, and M.C. Recio. 2012. Cucurbitacins as inducers of cell death and a rich source of potential anticancer compounds. Current Pharmaceutical Design 18: 1663-1676.
PLoS ONE J Salotti 8 e72582 2013 10.1371/journal.pone.0072582 Salotti, J., M.H. Dias, M.M. Koga, and H.A. Armelin. 2013. Fibroblast growth factor 2 causes G2/M cell cycle arrest in Ras-driven tumor cells through a Src-dependent pathway. PLoS ONE 8: e72582.
Cancer Letters S Saraswati 332 83 2013 10.1016/j.canlet.2013.01.012 Saraswati, S., and S.S. Agrawal. 2013. Brucine, an indole alkaloid from Strychnos nux-vomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivo. Cancer Letters 332: 83-93.
PLoS ONE SM Smith 6 e26908 2011 10.1371/journal.pone.0026908 Smith, S.M., M.B. Wunder, D.A. Norris, and Y.G. Shellman. 2011. A simple protocol for using a LDH-based cytotoxicity assay to assess the effects of death and growth inhibition at the same time. PLoS ONE 6: e26908.
Biochemical Journal J Wesche 437 199 2011 10.1042/BJ20101603 Wesche, J., K. Haglund, and E.M. Haugsten. 2011. Fibroblast growth factors and their receptors in cancer. Biochemical Journal 437: 199-213.
Current Topics in Microbiology and Immunology A Wiedłocha 286 45 2004 Wiedłocha, A., and V. Sørensen. 2004. Signaling, internalization, and intracellular activity of fibroblast growth factor. Current Topics in Microbiology and Immunology 286: 45-79.
Journal of Pharmacology and Experimental Therapeutics Y Wu 339 403 2011 10.1124/jpet.111.181891 Wu, Y., L. He, L. Zhang, J. Chen, Z. Yi, J. Zhang, M. Liu, and X. Pang. 2011. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway. Journal of Pharmacology and Experimental Therapeutics 339: 403-411.
American Journal of Physiology: Renal Physiology T Wu 304 F820 2013 Wu, T., B. Zhang, F. Ye, and Z. Xiao. 2013. A potential role for caveolin-1 in VEGF-induced fibronectin upregulation in mesangial cells: Involvement of VEGFR2 and Src. American Journal of Physiology: Renal Physiology 304: F820-F830.
Molecular Medicine Reports Z Zhao 5 788 2012 Zhao, Z., L. Holle, W. Song, Y. Wei, T.E. Wagner, and X. Yu. 2012. Antitumor and anti-angiogenic activities of Scutellaria barbata extracts in vitro are partially mediated by inhibition of Akt/protein kinase B. Molecular Medicine Reports 5: 788-792.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.